TY - JOUR
T1 - Supplement to the 2004 update of the AAPM Task Group No. 43 Report
AU - Rivard, Mark J.
AU - Butler, Wayne M.
AU - DeWerd, Larry A.
AU - Huq, M. Saiful
AU - Ibbott, Geoffrey S.
AU - Meigooni, Ali S.
AU - Melhus, Christopher S.
AU - Mitch, Michael G.
AU - Nath, Ravinder
AU - Williamson, Jeffrey F.
N1 - Funding Information:
The authors wish to thank Frank A. Ibbott for creation of the artwork in Fig. , which was supported by the AAPM Therapy Physics Committee (TPC). Also, we extend our appreciation to Sujat Suthankar of Rosses Medical Systems (now at Implant Sciences) for discussions on Sec. . Furthermore, we thank Janelle A. Molloy for AAPM TPC review and Zuofeng Li, Ning J. Yue, and Bruce Thomadsen of the AAPM BTSC for their constructive comments and careful review of this report. We also wish to thank David W. O. Rogers for bringing the air mass density correction to our attention. Some of the authors (M.J.R.; A.S.M.; R.N.; J.F.W.) have received research support to perform dosimetry studies for the sources included herein (Implant Sciences Corp., Mills Biopharmaceuticals Corp.; International Brachytherapy, IsoAid Corp., and Best Medical Inc.; DraxImage Inc.; DraxImage Inc. and SourceTech Medical, respectively).
PY - 2007
Y1 - 2007
N2 - Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical use as of January 10, 2005, and are posted on the Joint AAPM/RPC Brachytherapy Seed Registry. Consequently, the AAPM has prepared this supplement to the 2004 AAPM TG-43 update. This paper presents the AAPM-approved consensus datasets for these sources, and includes the following I125 sources: Amersham model 6733, Draximage model LS-1, Implant Sciences model 3500, IBt model 1251L, IsoAid model IAI-125A, Mentor model SL-125/SH-125, and SourceTech Medical model STM1251. The Best Medical model 2335 Pd103 source is also included. While the methodology used to determine these data sets is identical to that published in the AAPM TG-43U1 report, additional information and discussion are presented here on some questions that arose since the publication of the TG-43U1 report. Specifically, details of interpolation and extrapolation methods are described further, new methodologies are recommended, and example calculations are provided. Despite these changes, additions, and clarifications, the overall methodology, the procedures for developing consensus data sets, and the dose calculation formalism largely remain the same as in the TG-43U1 report. Thus, the AAPM recommends that the consensus data sets and resultant source-specific dose-rate distributions included in this supplement be adopted by all end users for clinical treatment planning of low-energy photon-emitting brachytherapy sources. Adoption of these recommendations may result in changes to patient dose calculations, and these changes should be carefully evaluated and reviewed with the radiation oncologist prior to implementation of the current protocol.
AB - Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical use as of January 10, 2005, and are posted on the Joint AAPM/RPC Brachytherapy Seed Registry. Consequently, the AAPM has prepared this supplement to the 2004 AAPM TG-43 update. This paper presents the AAPM-approved consensus datasets for these sources, and includes the following I125 sources: Amersham model 6733, Draximage model LS-1, Implant Sciences model 3500, IBt model 1251L, IsoAid model IAI-125A, Mentor model SL-125/SH-125, and SourceTech Medical model STM1251. The Best Medical model 2335 Pd103 source is also included. While the methodology used to determine these data sets is identical to that published in the AAPM TG-43U1 report, additional information and discussion are presented here on some questions that arose since the publication of the TG-43U1 report. Specifically, details of interpolation and extrapolation methods are described further, new methodologies are recommended, and example calculations are provided. Despite these changes, additions, and clarifications, the overall methodology, the procedures for developing consensus data sets, and the dose calculation formalism largely remain the same as in the TG-43U1 report. Thus, the AAPM recommends that the consensus data sets and resultant source-specific dose-rate distributions included in this supplement be adopted by all end users for clinical treatment planning of low-energy photon-emitting brachytherapy sources. Adoption of these recommendations may result in changes to patient dose calculations, and these changes should be carefully evaluated and reviewed with the radiation oncologist prior to implementation of the current protocol.
KW - Brachytherapy
KW - Dosimetry protocol
KW - TG-43
UR - http://www.scopus.com/inward/record.url?scp=34447302063&partnerID=8YFLogxK
U2 - 10.1118/1.2736790
DO - 10.1118/1.2736790
M3 - Article
C2 - 17654921
AN - SCOPUS:34447302063
SN - 0094-2405
VL - 34
SP - 2187
EP - 2205
JO - Medical physics
JF - Medical physics
IS - 6
ER -